Workgroup Environment, Occupational Safety and Chemicals
This specialist workgroup consists of specialists from member companies whose main focus is on industrial environmental protection with its legal framework conditions and occupational safety in processing companies. The involvement in international viewpoints for occupational safety in internationally active companies plays just as much a key role as the new legislative initiatives in environmental issues on a European and national level.
The workgroup Environment & Occupational Safety is an expert committee of specialists in the field of industrial environmental protection and occupational safety in the companies in part with international responsibilities. In the workgroup all important topics in this field are dealt with, information exchanged and experiences promoted, and contacts with public authorities and ministries cultivated. The workgroup deals with the implementation of new laws and regulations and in part works out implementation information.
Speakers are: Rebecca Ebermann-Finken, Dr. Holger Klyszcz – Nasko, Roland Schneider
Aktion Einspruch gegen REACH in Berlin 2005
Kundgebung und Demonstration vor dem Brandenburger Tor in Berlin am 21.04.2005
Bayer AG Forschung
Bayer HealthCare ist international führend in der Entwicklung, Herstellung und dem Vertrieb von Medikamenten zur Behandlung der Bluterkrankheit. Im Bild ein Labor des US-Biotechnologie-Unternehmens Avigen, das zu den ersten Adressen bei der Entwicklung von neuen Behandlungsmöglichkeiten durch Gentransfer zählt. Im Rahmen eines Abkommens hat Bayer von Avigen weltweit die exklusiven Vermarktungs- und Vertriebsrechte für die Gentherapie Coagulin-B zur Behandlung der Bluterkrankheit Hämophilie B erhalten.
Leverkusen, November 2004
Foto: Bayer AG
Abdruck mit Urhebervermerk honorarfrei.
Bayer HealthCare is an international leader in the development, manufacture and distribution of drugs to treat hemophilia. The picture shows a laboratory at the U.S. biotech company Avigen, one of the world's outstanding players in the development of new treatment options based on gene transfer. Bayer has concluded an agreement with Avigen to acquire exclusive global marketing and distribution rights for Avigen's gene therapy Coagulin-B for the treatment of hemophilia B.
Leverkusen, November 2004
Photo: Bayer AG
Photo may be reproduced free of charge.
Please credit "Photo: Bayer AG"
News
FSK discusses sustainability at John Deere, agricultural machinery manufacturer
Frankfurt (FSK). Sustainability, environmental issues and recycling were the main topics at the meeting of the Specialist Association Foamed Plastics and Polyurethanes (FSK) at John Deere, agricultural machinery and vehicle manufacturer, in...[more]
Close the gaps in the CE-Marking of equipment for plastics processing!
Frankfurt (FSK). “Liability and work safety hazards are slumbering at many plastics processors due to the non-existence of CE-markings on machines and production lines as called for by Equipment Safety Laws'', is how Rebecca Ebermann-Finken, the...[more]